drugset / Trial / NCT00647933

An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Org 36286 (P07004)

NCT00647933

Phase 1 Completed 24 enrolled Organon and Co
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objectives of this study were to study the pharmacokinetics, pharmacodynamics and safety of Org 36286 after a single subcutaneous administration in healthy females.

Timeline

Start
2000-06
Primary completion
2000-12
Completion
2000-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Corifollitropin alfa Protein / enzyme biologic 15 ug Subcutaneous
Subject Corifollitropin alfa Protein / enzyme biologic 30 ug Subcutaneous
Subject Corifollitropin alfa Protein / enzyme biologic 60 ug Subcutaneous
Subject Corifollitropin alfa Protein / enzyme biologic 120 ug Subcutaneous
Background Lynestrenol Small molecule 2.5 mg Oral
Background ethinyl estradiol Small molecule 50 ug Oral

Indications